Portfolio at a glance
Securities as at December 31, 2020
|
Company |
|
Number of securities |
|
Change since 31.12.2019 |
|
Local currency |
|
Share price |
|
Market value in CHF mn |
|
In % of securities |
|
In % of shareholders' equity |
|
In % of company |
|
Ionis Pharmaceuticals |
|
8 220 000 |
|
225 045 |
|
USD |
|
56.54 |
|
411.4 |
|
10.4% |
|
10.6% |
|
5.9% |
|
Moderna |
|
2 854 963 |
|
(1 962 818) |
|
USD |
|
104.47 |
|
264.0 |
|
6.7% |
|
6.8% |
|
0.7% |
|
Neurocrine Biosciences |
|
3 035 000 |
|
(193 074) |
|
USD |
|
95.85 |
|
257.5 |
|
6.5% |
|
6.6% |
|
3.2% |
|
Argenx SE |
|
921 332 |
|
(23 407) |
|
USD |
|
294.09 |
|
239.8 |
|
6.1% |
|
6.2% |
|
1.9% |
|
Incyte |
|
2 900 000 |
|
(500 000) |
|
USD |
|
86.98 |
|
223.3 |
|
5.6% |
|
5.7% |
|
1.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vertex Pharmaceuticals |
|
900 000 |
|
(340 000) |
|
USD |
|
236.34 |
|
188.3 |
|
4.8% |
|
4.8% |
|
0.3% |
|
Alexion Pharmaceuticals |
|
1 294 428 |
|
(20 000) |
|
USD |
|
156.24 |
|
179.0 |
|
4.5% |
|
4.6% |
|
0.6% |
|
Arvinas |
|
2 176 903 |
|
935 000 |
|
USD |
|
84.93 |
|
163.7 |
|
4.1% |
|
4.2% |
|
4.6% |
|
Fate Therapeutics |
|
2 030 000 |
|
2 030 000 |
|
USD |
|
90.93 |
|
163.4 |
|
4.1% |
|
4.2% |
|
2.3% |
|
Agios Pharmaceuticals |
|
4 158 902 |
|
261 948 |
|
USD |
|
43.33 |
|
159.5 |
|
4.0% |
|
4.1% |
|
6.0% |
|
Halozyme Therapeutics |
|
3 970 000 |
|
(3 993 056) |
|
USD |
|
42.71 |
|
150.1 |
|
3.8% |
|
3.9% |
|
3.0% |
|
Alnylam Pharmaceuticals |
|
1 155 000 |
|
(445 000) |
|
USD |
|
129.97 |
|
132.9 |
|
3.4% |
|
3.4% |
|
1.0% |
|
Crispr Therapeutics |
|
900 884 |
|
170 422 |
|
USD |
|
153.11 |
|
122.1 |
|
3.1% |
|
3.1% |
|
1.2% |
|
Sage Therapeutics |
|
1 540 104 |
|
260 000 |
|
USD |
|
86.51 |
|
117.9 |
|
3.0% |
|
3.0% |
|
3.0% |
|
Radius Health |
|
7 455 714 |
|
574 029 |
|
USD |
|
17.86 |
|
117.9 |
|
3.0% |
|
3.0% |
|
16.0% |
|
Biogen |
|
537 000 |
|
537 000 |
|
USD |
|
244.86 |
|
116.4 |
|
2.9% |
|
3.0% |
|
0.3% |
|
Myovant Sciences |
|
4 757 039 |
|
(58 070) |
|
USD |
|
27.62 |
|
116.3 |
|
2.9% |
|
3.0% |
|
5.3% |
|
Intra-Cellular Therapies |
|
3 538 419 |
|
1 238 419 |
|
USD |
|
31.80 |
|
99.6 |
|
2.5% |
|
2.6% |
|
4.4% |
|
Macrogenics |
|
4 815 564 |
|
296 405 |
|
USD |
|
22.86 |
|
97.4 |
|
2.5% |
|
2.5% |
|
8.4% |
|
Scholar Rock Holding |
|
2 255 651 |
|
(378 815) |
|
USD |
|
48.53 |
|
96.9 |
|
2.5% |
|
2.5% |
|
6.7% |
|
Esperion Therapeutics |
|
3 947 964 |
|
220 000 |
|
USD |
|
26.00 |
|
90.9 |
|
2.3% |
|
2.3% |
|
14.2% |
|
Generation Bio Co. |
|
2 333 180 |
|
2 333 180 |
|
USD |
|
28.35 |
|
58.6 |
|
1.5% |
|
1.5% |
|
5.0% |
|
Molecular Templates |
|
6 380 331 |
|
5 084 644 |
|
USD |
|
9.39 |
|
53.0 |
|
1.3% |
|
1.4% |
|
12.8% |
|
Relay Therapeutics |
|
1 409 357 |
|
1 409 357 |
|
USD |
|
41.56 |
|
51.8 |
|
1.3% |
|
1.3% |
|
1.6% |
|
Exelixis |
|
2 835 000 |
|
– |
|
USD |
|
20.07 |
|
50.4 |
|
1.3% |
|
1.3% |
|
0.9% |
|
Mersana Therapeutics |
|
1 885 000 |
|
1 885 000 |
|
USD |
|
26.61 |
|
44.4 |
|
1.1% |
|
1.1% |
|
2.8% |
|
Nektar Therapeutics |
|
2 620 676 |
|
– |
|
USD |
|
17.00 |
|
39.4 |
|
1.0% |
|
1.0% |
|
1.5% |
|
Black Diamond Therapeutics |
|
1 390 000 |
|
1 390 000 |
|
USD |
|
32.05 |
|
39.4 |
|
1.0% |
|
1.0% |
|
3.9% |
|
Beam Therapeutics |
|
396 821 |
|
396 821 |
|
USD |
|
81.64 |
|
28.7 |
|
0.7% |
|
0.7% |
|
0.7% |
|
Kezar Life Sciences |
|
4 533 148 |
|
2 982 479 |
|
USD |
|
5.22 |
|
20.9 |
|
0.5% |
|
0.5% |
|
9.8% |
|
Wave Life Sciences |
|
2 602 858 |
|
200 000 |
|
USD |
|
7.87 |
|
18.1 |
|
0.5% |
|
0.5% |
|
5.3% |
|
Homology Medicines |
|
1 737 122 |
|
125 000 |
|
USD |
|
11.29 |
|
17.4 |
|
0.4% |
|
0.4% |
|
3.8% |
|
Voyager Therapeutics |
|
2 680 283 |
|
– |
|
USD |
|
7.15 |
|
17.0 |
|
0.4% |
|
0.4% |
|
7.2% |
|
Cidara Therapeutics |
|
2 822 495 |
|
527 223 |
|
USD |
|
2.00 |
|
5.0 |
|
0.1% |
|
0.1% |
|
6.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alder Biopharmaceuticals – Contingent Value Right |
|
2 766 008 |
|
– |
|
USD |
|
0.88 |
|
2.2 |
|
0.1% |
|
0.1% |
|
|
|
Bristol-Myers Squibb – Contingent Value Right |
|
800 000 |
|
– |
|
USD |
|
0.00 |
|
0.0 |
|
0.0% |
|
0.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total securities |
|
|
|
|
|
|
|
|
|
3 954.7 |
|
100.0% |
|
101.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other assets |
|
|
|
|
|
|
|
|
|
8.4 |
|
|
|
0.2% |
|
|
|
Other payables |
|
|
|
|
|
|
|
|
|
(75.6) |
|
|
|
(1.9%) |
|
|
|
Net asset value |
|
|
|
|
|
|
|
|
|
3 887.5 |
|
|
|
100.0% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BB Biotech registered shares 1) |
|
114 662 |
|
114 662 |
|
|
|
|
|
8.5 |
|
|
|
|
|
0.2% |
1 Correspond to the total of all own shares held including the second trading line
Exchange rate as at 31.12.2020: USD/CHF: 0.8852